Clinical Trials Logo

Dysbiosis clinical trials

View clinical trials related to Dysbiosis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06374407 Not yet recruiting - Obesity Clinical Trials

The MIND-GUT Digital Pilot Intervention Study

MINDGUT
Start date: June 2024
Phase: N/A
Study type: Interventional

This 12-week pilot study aims to evaluate the feasibility and effectiveness of a dietary intervention targeting diet, obesity, mental health, and the gut microbiome in promoting weight loss and enhancing mental health among obese men and women aged 30-50. Participants, excluding those with specific medical conditions, will be randomly assigned to either an intervention or control group using a meal planning smartphone app. Clinical assessments will include anthropometry, mental health questionnaires, dietary recalls, and stool sample collections. The study's endpoints include program retention, adherence, changes in body weight, mental health, and gut microbiome diversity. Statistical analyses will evaluate intervention effects and the potential mediating roles of the gut microbiome. This pilot study has implications for health policies, public healthcare, digital health companies, and the biotech and pharmacology industries. Future plans involve a large-scale intervention study in multiple countries with ongoing collaborations.

NCT ID: NCT06349122 Not yet recruiting - Bacterial Vaginosis Clinical Trials

Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth

AUTOP2
Start date: August 2024
Phase: Phase 4
Study type: Interventional

Preterm birth is an important cause of death and disabilities. Bacterial vaginosis (BV) is a common vaginal dysbiosis or abnormal microbiota, with a predominance of anaerobic bacteria with a lack of Lactobacillus, with various diagnosis methods. Often asymptomatic, BV increases the risk of preterm birth according to the gestational age at diagnosis. BV is usually diagnosed by conventional diagnosis such as Nugent score. Molecular diagnosis of BV has been demonstrated to be more reproducible, more accurate and to better define dysbiosis. The main objective of the study is to evaluate the effectiveness of an innovative screen-and-treat strategy for vaginal flora abnormalities by molecular biology using a Point of Care multiplex technology before 18 weeks' gestation to reduce the rate of preterm birth in a population of pregnant women at high risk of preterm birth. The hypothesis is that a strategy for screening and treating vaginal flora abnormalities and their recurrences using molecular biology in women with a history of prematurity or late-term abortion could be effective in reducing premature births by 40%.

NCT ID: NCT06329596 Not yet recruiting - Dysbiosis Clinical Trials

Microbiome Alterations With Xylitol (MAX) in Pregnancy

MAX
Start date: June 13, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to understand if chewing xylitol-gum initiated before 20 weeks of pregnancy and continued until delivery affects the bacteria that are found in the oral and vaginal cavities, signs of inflammation within the gingiva of the oral cavity, the health of the tissues in the mouth (clinical parameters of periodontal disease), and the bacteria in the mouth and gut of newborns among pregnant individuals in Malawi.

NCT ID: NCT06231849 Not yet recruiting - Opioid Use Clinical Trials

Gut Microbiota Dysbiosis in Opioid Use Disorders: Implications for Clinical Symptoms and Relapse Rate.

Start date: February 2024
Phase:
Study type: Observational

This study will aim to investigate the gut microbiota in Egyptian patients with opioid use disorders and correlate microbiota bacterial abundance with clinical data.

NCT ID: NCT06231303 Not yet recruiting - Clinical trials for Gut Microbiota Dysbiosis in Lupus Nepheritis

Gut Microbiota Dysbiosis in Lupus Nephritis

Start date: January 2025
Phase:
Study type: Observational

Evaluate dysbiosis of some intestinal microbiota in adult patients with lupus nephritis compared to healthy controls.

NCT ID: NCT06161285 Not yet recruiting - Bronchiolitis Clinical Trials

Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants

BRONCHOBIOTE
Start date: April 2024
Phase: N/A
Study type: Interventional

Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV). Furthermore, given the same medical history, it is still very difficult to predict the course and severity of the infection at the onset of symptoms, Some studies have highlighted the importance of the microbiota (intestinal, oral or nasopharyngeal) and of the immune response to RSV in children, We will include 80 children under 2 years old with hospitalized bronchiolitis and non-hospitalized bronchiolitis. Oral, nasal and stool samples will be taken to study the various microbiota in search of dysbiosis. A capillary blood sample will be taken for immune studies.

NCT ID: NCT06114303 Not yet recruiting - Dysbiosis Clinical Trials

Ex-vivo Evaluation of the Effect of 2 Probiotic Solutions (Lactibiane ATB and Lactibiane Enfant) and 5 Classes of Drugs on the Intestinal Microbiota

EPROMED
Start date: January 20, 2025
Phase:
Study type: Observational

The objective is to test ex-vivo the effects of two probiotic solutions (Lactibiane ATB and Lactibiane Enfant) and five classes of drugs (antibiotic, proton pump inhibitor, non-steroidal anti-inflammatory, anxiolytic and anti-depressant) on microbial microcosms derived from human stool samples (from adults and children) re-cultured under anaerobic conditions.

NCT ID: NCT06040164 Not yet recruiting - Obesity Clinical Trials

Oral Endocannabinoids in People With Prediabetes and Diabetes

SMILE
Start date: October 1, 2023
Phase:
Study type: Observational

This study evaluates the relationship of endocannabinoids in saliva with inflammation and oral dysbacteriosis present in people with periodontal disease and prediabetes/type 2 diabetes

NCT ID: NCT05813184 Not yet recruiting - Dysbiosis Clinical Trials

Prenatal Antibiotics and Breast Milk / Neonatal IgA

PAIGAN 1
Start date: April 30, 2023
Phase:
Study type: Observational

In this biological study, we will evaluate the levels of breast milk IgA, neonatal fecal IgA, and the composition of breast milk and fecal microbiota throughout the first 12 months of life in neonates born to mothers treated or not treated with prenatal antibiotics for at least 7 days after the 32nd weeks of gestation

NCT ID: NCT05554185 Not yet recruiting - Clinical trials for PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy

Probiotic Supplementation During Pregnancy in Preeclampsia High-risk Groups

Start date: September 21, 2022
Phase: N/A
Study type: Interventional

In this randomized controlled study, preventive intervention of aspirin combined with probiotics or aspirin combined with placebo would given to PE (pre-eclampsia) high-risk population with gut microbiota dysbiosis during their pregnancy, and finally assess the efficacy and safety of aspirin combined with probiotics to prevent PE.